title: Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain.
abstract: Viral vectors are a commonly used method for gene therapy because of their highly efficient transduction of cells. However, many vectors have a small genetic capacity, and their potential for immunogenicity can limit their usefulness. Moreover, for disorders of the central nervous system (CNS), the need for invasive surgical delivery of viruses to the brain also detracts from their clinical applicability. Here, we show that intranasal delivery of unimolecularly compacted DNA nanoparticles (DNA NPs), which consist of single molecules of plasmid DNA encoding enhanced green fluorescent protein (eGFP) compacted with 10 kDa polyethylene glycol (PEG)-substituted lysine 30-mers (CK30PEG10k), successfully transfect cells in the rat brain. Direct eGFP fluorescence microscopy, eGFP-immunohistochemistry (IHC) and eGFP-ELISA all demonstrated eGFP protein expression 2 days after intranasal delivery. eGFP-positive cells were found throughout the rostral-caudal axis of the brain, most often adjacent to capillary endothelial cells. This localization provides evidence for distribution of the nasally administered DNA NPs via perivascular flow. These results are the first report that intranasal delivery of DNA NPs can bypass the blood-brain barrier and transfect and express the encoded protein in the rat brain, affording a non-invasive approach for gene therapy of CNS disorders.
authors.affiliation: Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
authors.forename: B T
authors.initials: BT
authors.lastname: Harmon
authors.affiliation: Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Aly
authors.affiliation: Copernicus Therapeutics, Inc., Cleveland, OH, USA.
authors.forename: L
authors.initials: L
authors.lastname: Padegimas
authors.affiliation: Copernicus Therapeutics, Inc., Cleveland, OH, USA.
authors.forename: O
authors.initials: O
authors.lastname: Sesenoglu-Laird
authors.affiliation: Copernicus Therapeutics, Inc., Cleveland, OH, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Cooper
authors.affiliation: Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
authors.forename: B L
authors.initials: BL
authors.lastname: Waszczak
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000502:physiology; D004270:DNA, Circular / Q000008:administration & dosage*; D015870:Gene Expression; D017930:Genes, Reporter; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins / Q000008:administration & dosage / Q000235:genetics; D008297:Male; D053758:Nanoparticles / Q000008:administration & dosage*; D010957:Plasmids / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014162:Transfection / Q000379:methods*
chemical_list: D004270:DNA, Circular; D049452:Green Fluorescent Proteins